Gilead Sciences and JD Health Announce Strategic Collaboration to Build an Integrated 'Internet + Chronic Infectious Diseases' Service Platform

SHANGHAI, July 9, 2021 /PRNewswire/ -- On July 9, 2021, Gilead Sciences and JD Health entered into a strategic partnership in the digital healthcare ecosystem. Leveraging Gilead Sciences' expertise in the antiviral field,Specialties andLeveraging JD Health's advantages in the internet sector, both parties will deeply explore innovative practices in “Internet + Healthcare”, jointly providing more professional, safe, and convenient “one-stop” disease management solutions for patients with chronic infectious diseases, thereby accelerating progress in the prevention and control of infectious diseases such as HIV and chronic viral hepatitis.

Signing Ceremony of the Strategic Cooperation Memorandum of Understanding

According to the Memorandum of Cooperation, JD Health will establish the JD Pharmacy Liver Disease Care Center and HIV Care Center, with planned support from Gilead. Taking HIV and chronic viral hepatitis—two major chronic infectious diseases—as strategic entry points, the initiative aims to leverage the convenience of internet platforms to enhance the accessibility and ease of access to innovative medications. This will help improve patients' medication adherence, ultimately leading to better therapeutic outcomes. Additionally, the platform plans to regularly host medical education seminars to enhance disease awareness among patients and the general public, collaborating to co-develop an integrated online-to-offline, full-cycle service system for the management, prevention, and control of chronic infectious diseases.

The strong alignment between the two parties in vision and development objectives has laid a solid foundation for this collaboration. Based on the strategic positioning of “a digitally-driven health management platform covering users’ entire life cycles and all scenarios, with the supply chain as its core and medical services as its key driver,” JD Health has established a comprehensive and complete “Internet + Healthcare” ecosystem. It has built an integrated online-and-offline health management model that delivers convenient, efficient, professional, and secure internet healthcare services to patients.

Regarding this collaboration, Mr. Xin Lijun, Senior Vice President of JD Group and CEO of JD Health, stated: “In recent years, through the expansion of service scenarios and the optimization of the service delivery chain, JD Health has effectively integrated ‘Internet + Healthcare’ into the daily lives of a broad user base. Through this in-depth collaboration, we will leverage Gilead Sciences’ leading expertise in the antiviral field. Beyond addressing patients’ treatment needs, we will also actively explore the potential of utilizing internet technology to enhance the prevention and control of infectious diseases, contributing our share to meeting the practical needs of global public well-being.”

Mr. Xin Lijun, Senior Vice President of JD Group and CEO of JD Health

As a biopharmaceutical company with extensive expertise in the antiviral field, Gilead Sciences has been dedicated to advancing pharmaceutical innovation over the past three decades, achieving multiple breakthroughs once deemed medically impossible. Since entering the Chinese market, the company has continuously expanded access to innovative medicines by introducing eight globally innovative drugs to China for the treatment of chronic hepatitis B, hepatitis C, and HIV. Of these, four have been included in the National Reimbursement Drug List (NRDL), successfully enabling more patients to access first-line innovative therapies at affordable prices.

In recent years, Gilead Sciences has been continuously exploring innovative models to leverage the Internet and emerging technologies to further expand the accessibility of innovative medicines. In the context of normalized epidemic prevention and control, Gilead is increasingly committed to collaborating with partners to expand online channels across multiple touchpoints. By harnessing the advantages of the Internet, Gilead aims to ensure that Internet-based healthcare serves not only as a convenient online channel for medication purchases, but also as a platform that delivers high-quality, professional, and comprehensive healthcare services tailored to the genuine needs of users today.

Mr. Jin Fangqian, Global Vice President and General Manager, China, Gilead Sciences

Global Vice President, Gilead Sciences、China RegionMr. Jin Fangqian, General Manager, stated: “Since its establishment, Gilead has consistently upheld a ‘patient-centric’ philosophy. We not only continue to deliver breakthrough innovative medicines, but also persistently explore and pioneer new channels and service models to tangibly benefit patients. The future of ‘Internet + Healthcare’ holds boundless possibilities. Through this collaboration with JD Health, we look forward to leveraging our respective strengths. Starting from patients’ unmet needs, and while focusing on individualized care and enhancing the disease management experience, we will also broaden our vision to address wider public health challenges. Together, we aim to explore innovative models for infectious disease management and prevention, committed to creating a better and healthier world for the public.”